Experts question GAVI’s choice of vaccine

News May 04, 2009

Based on a donation by the Wyeth pharmaceutical company, GAVI recently launched the pneumococcal vaccine, Prevenar, in Rwanda, a first in Africa. Experts question the suitability of the vaccine in the African context, and GAVI’s decision to approve its use.

If you are new to Development Today and would like to continue reading this article, send us a mail at subscribers@devtoday.no, including your name, title, organisation, and email contact, and you will receive a free Guest Pass, along with weekly updates.